A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort
Abstract Introduction Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of the...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14270-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226225795465216 |
|---|---|
| author | Nihanthy D. Sreenath Suresh Pandalanghat Amul Kapoor Rajath Govind M. R. Kaushik Rajesh Nair Dipen Bhuva Anvesh Rathore Manish Kumar Deepak Mulajker |
| author_facet | Nihanthy D. Sreenath Suresh Pandalanghat Amul Kapoor Rajath Govind M. R. Kaushik Rajesh Nair Dipen Bhuva Anvesh Rathore Manish Kumar Deepak Mulajker |
| author_sort | Nihanthy D. Sreenath |
| collection | DOAJ |
| description | Abstract Introduction Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of these agents globally, real-world data from India is limited. This study compares the clinical effectiveness and safety profiles of Palbociclib and Ribociclib in a cohort of Indian patients. Materials and methods This prospective study included 60 patients with metastatic HR+/HER2- breast cancer treated at Army hospitals and research centers in India between 2020 and 2023. Progression-free survival (PFS), overall survival (OS), and safety profiles were analyzed to assess the real-world performance of Palbociclib and Ribociclib. Patients were treated with either Palbociclib or Ribociclib in combination with standard endocrine therapy. Results Among the 60 patients, the median PFS was 39.40 months for the Palbociclib group and 42.93 months for the Ribociclib group (p = 0.26), indicating no statistically significant difference. The median OS was 41.98 months in the Palbociclib group and 45.51 months in the Ribociclib group (p = 0.15), with Ribociclib showing a slight but non-significant survival advantage. The most common adverse event was neutropenia, which occurred in 26% of patients receiving Palbociclib and 23% of patients on Ribociclib. Deranged liver function tests (LFTs) and fatigue were also reported in both groups. Conclusions Palbociclib and Ribociclib demonstrated comparable efficacy and safety profiles in this Indian cohort. While no statistically significant differences in PFS or OS were observed, the data suggest a marginal survival benefit with Ribociclib. These findings underscore the importance of individualized treatment plans in HR+/HER2- breast cancer, taking into consideration patient-specific factors. Larger studies with longer follow-up are needed to further clarify the nuances between these two agents. |
| format | Article |
| id | doaj-art-9602914ffa78439eba97677fc8db7c73 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-9602914ffa78439eba97677fc8db7c732025-08-24T11:34:48ZengBMCBMC Cancer1471-24072025-08-012511910.1186/s12885-025-14270-1A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohortNihanthy D. Sreenath0Suresh Pandalanghat1Amul Kapoor2Rajath Govind3M. R. Kaushik4Rajesh Nair5Dipen Bhuva6Anvesh Rathore7Manish Kumar8Deepak Mulajker9Saroj Gupta Cancer Centre & Research InstituteMedicine & Medical Oncology, Army Hospital (R&R)Medicine & Medical Oncology, Army Hospital (R&R)Medicine & Medical Oncology, Army Hospital (R&R)Medicine & Medical Oncology, INHS AsviniMedicine & Medical Oncology, Command Hospital (Central Command)Blood and Cancer InstituteMedicine & Medical Oncology, Army Hospital (R&R)Medicine & Medical Oncology, Army Hospital (R&R)Medicine & Medical Oncology, Army Hospital (R&R)Abstract Introduction Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of these agents globally, real-world data from India is limited. This study compares the clinical effectiveness and safety profiles of Palbociclib and Ribociclib in a cohort of Indian patients. Materials and methods This prospective study included 60 patients with metastatic HR+/HER2- breast cancer treated at Army hospitals and research centers in India between 2020 and 2023. Progression-free survival (PFS), overall survival (OS), and safety profiles were analyzed to assess the real-world performance of Palbociclib and Ribociclib. Patients were treated with either Palbociclib or Ribociclib in combination with standard endocrine therapy. Results Among the 60 patients, the median PFS was 39.40 months for the Palbociclib group and 42.93 months for the Ribociclib group (p = 0.26), indicating no statistically significant difference. The median OS was 41.98 months in the Palbociclib group and 45.51 months in the Ribociclib group (p = 0.15), with Ribociclib showing a slight but non-significant survival advantage. The most common adverse event was neutropenia, which occurred in 26% of patients receiving Palbociclib and 23% of patients on Ribociclib. Deranged liver function tests (LFTs) and fatigue were also reported in both groups. Conclusions Palbociclib and Ribociclib demonstrated comparable efficacy and safety profiles in this Indian cohort. While no statistically significant differences in PFS or OS were observed, the data suggest a marginal survival benefit with Ribociclib. These findings underscore the importance of individualized treatment plans in HR+/HER2- breast cancer, taking into consideration patient-specific factors. Larger studies with longer follow-up are needed to further clarify the nuances between these two agents.https://doi.org/10.1186/s12885-025-14270-1CDK4/6 inhibitorsHR+/HER2- breast cancerMetastatic breast cancerPalbociclibRibociclibReal-world evidence |
| spellingShingle | Nihanthy D. Sreenath Suresh Pandalanghat Amul Kapoor Rajath Govind M. R. Kaushik Rajesh Nair Dipen Bhuva Anvesh Rathore Manish Kumar Deepak Mulajker A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort BMC Cancer CDK4/6 inhibitors HR+/HER2- breast cancer Metastatic breast cancer Palbociclib Ribociclib Real-world evidence |
| title | A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort |
| title_full | A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort |
| title_fullStr | A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort |
| title_full_unstemmed | A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort |
| title_short | A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort |
| title_sort | comparative analysis of palbociclib and ribociclib in metastatic hormone receptor positive her2 negative breast cancer a prospective mid term follow up study from an indian cohort |
| topic | CDK4/6 inhibitors HR+/HER2- breast cancer Metastatic breast cancer Palbociclib Ribociclib Real-world evidence |
| url | https://doi.org/10.1186/s12885-025-14270-1 |
| work_keys_str_mv | AT nihanthydsreenath acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT sureshpandalanghat acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT amulkapoor acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT rajathgovind acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT mrkaushik acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT rajeshnair acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT dipenbhuva acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT anveshrathore acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT manishkumar acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT deepakmulajker acomparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT nihanthydsreenath comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT sureshpandalanghat comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT amulkapoor comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT rajathgovind comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT mrkaushik comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT rajeshnair comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT dipenbhuva comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT anveshrathore comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT manishkumar comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort AT deepakmulajker comparativeanalysisofpalbociclibandribociclibinmetastatichormonereceptorpositiveher2negativebreastcanceraprospectivemidtermfollowupstudyfromanindiancohort |